Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy in HIV/AIDS patients

Antiviral Chemistry and Chemotherapy

Volumn 14, Issue 5, 2003, Pages 281-284

  Dragovic, Gordana ^a   Jevtovic, Djordje ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Didanosine; Nucleoside reverse transcriptase inhibitors; Peripheral neuropathy; Stavudine

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE PANCREATITIS; ADOLESCENT; ADULT; ANEMIA; ARTICLE; CHILD; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LACTIC ACIDEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MYOPATHY; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 0344667703     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020301400507     Document Type: Article

References (15)

1. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S & Schon EA (1991) Depletion of mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 337:508-510.
2. Brinkman K, ter Hofstede HJM, Burger DM, Smeitink JAM & Koopmans PP (1988) Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12:1735-1744.
3. Cui L, Locatelli L, Xie MY & Sommadossi JP (1997) Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells. Journal of Pharmacology & Experimental Therapeutics 280:1228-1234.
4. Katlama C, Pellegrin JL, Lacoste D, Aquilina C, Raffi F, Vittecoq D, Raguin G, Lantz O, Mouroux M, Calvez V, Trylesinski A, Montestruc F, Dohin E, Goehrs JM & Delfraissy JF. (2001) MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine. HIV Medicine 2:20-26.
5. Lea AP & Faulds D (1996) Stavudine. A review of its pharmacodynamics and pharmacocinetic properties and clinical potential in HIV infection. Drugs 51:846-864.
6. Lelacheur SF & Simon GL (1991) Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine. Journal of Acquired Immune Deficiency Syndrome 4:538-539.
7. Moore RD, Wong WME, Keruly JC & McArthur JC (2000) Incidence of neuropathy in HIV infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS 14:273-278.
8. Moraes CT, Shanske S Tritschler H-J, Aprille JR, Andreetta F, Bonilla E, Schon EA & DiMauro S (1991) Mt DNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial diseases. American Journal of Human Genetics 48:492-501.
9. Moyle CJ & Sadler M (1998) Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drugs 19:481-494.
10. Reliquet V, Mussini JM, Chennebault JM, Lafeuillade A & Raffi F (2001) Peripheral neuropathy during stavudine-didanosine anti-retroviral therapy. HIV Medicine 2:92-96.
11. Schindzielorz A, Pike I, Daniels M, Pacelli L & Smaldone L (1994) Rates and risk factors for adverse events associated with didanosine in the expanded access program. Clinical Infectious Diseases 19:1076-1083.
12. Simpson DM & Olney RK (1992) Peripheral neuropaties associated with human immunodeficiency virus infection. Neurologic Clinics 10:685-711.
13. Simpson DM & Tagliati M (1995) Nucleoside analogue-asociated peripheral neuropathy in human immunodeficiency virus infection. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 9:153-161.
14. Sommadossi JP (1995) Comparison of metabolism and in vitro anti-retroviral activity of stavudine versus other 2′,3′ -dideoxynucleoside analogues. Journal of Infectious Diseases 171 (Suppl 2):S88-S92.
15. Sommadossi JP (1993) Nucleoside analogs: similarities and differences. Clinical Infectious Diseases 16 (Suppl 1):S7-S15.